Our Assets - NETRI

Our Assets.

Since 2018, NETRI has capitalized on its growing expertise to build a strong base of continuously expanding technical and production capabilities, as well as an international commercial footprint.

Know-how assets

• Microfluidics neuro-engineering
• Cell culture of hiPSC & primary cells
• Digital Tools

Explore

Production assets

• Microfluidic Devices Production Unit
• Cell Culture Production Unit
• R&D Labs

Explore

Commercial assets

• 9 proprietary patents
• 6 strategic partnerships
• 70 currents active clients

Explore

Know-How Assets.

NETRI has developped a recognized know-how in microfluidics neuro-engineering, cell culture of human induced pluripotent stem cells and digital tools developpement of neural network electrophysiological readouts and immunostaining methods.
Since 2018, we have nurture our skillsets in multiple microfluidics protocols and readouts: immunofluorescence, dedicated biomarkers, LC/MS, ELISA assays in microlfuidics devices.

Open innovation developement with our clients
9 cell seeding and culture/co-culture protocols
42 immunostaining protocols
Electrophysiological recording using Micro Electrodes Arrays
Scientific valorisation through peer reviewed publications, poster, international conferences

Production Assets.

NETRI manufactures devices and models using its pilot production units of microfluidic devices and cell culture automated labs. With more than 200 m² of production platform, 9 devices are marketed and divided into 2 lines, the NeuroFluidics™ and the NeuroFluidics™ MEA. Five types of neurons human cells derived from stem cells as well as primary keratinocytes are marketable with our devices.

In 2024, with the construction of its production site, NETRI will increase its production capacity of its pre-industrial pilot units with:

100 m² of ISO 8 laboratory for its ready-to-use devices production unit,
100 m² of P2 laboratory for its pre-industrial unit of pre-cultivated devices,
2 secure computing bays, for its artificial intelligence data analysis production unit and,
A dedicated area for its biobank.

Commercial Assets.

NETRI holds 9 proprietary patents and undisclosed manufacturing skillsets. Our devices are compatible with all cell types and we have estalished contracted partnerships with key cell suppliers, technologcial enablers and high content screening imaging and lab automation providers.

Since 2018, NETRI has established strategic partnerships to create commercial alliances, growth relays and provide innovative combined solutions to the healthcare ecosystem.

Axion BioSytems, technology supplier
Axol Biosciences, human iPSC-derived cells supplier
Tessara Therapeutics, 3D cell culture supplier
Etap lab, a CRO specialized in in vivo NDD
ACRO biosystems
Neuronexperts

Our Assets.

Know-how assets

Production assets

Commercial assets

Know-How Assets.

Production Assets.

Commercial Assets.

Contact us